Aviceda is a clinical-stage ophthalmology biotech developing therapies targeting geographic atrophy (GA) and diabetic macular edema (DME).

Founded by an experienced team of practicing ophthalmologists, Aviceda focuses on creating dual-targeted therapies to regulate the immune system to address inflammatory-driven ophthalmic disorders. Their lead program, AVD-104 is designed to inhibit both complement factor H (CFH) and macrophages. This dual mechanism distinguishes AVD-104 from existing GA therapies that exclusively target the complement system. The program aims to achieve improvements in best corrected visual acuity (BCVA), a critical clinical outcome that current therapies have been unable to deliver. Demonstrating BCVA improvements would address significant unmet needs and unlock considerable market potential by offering functional clinical benefits for patients.